Edwards Lifesciences Corp Stock Price, News & Analysis

Pulnovo Medical has appointed Dr. Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership.

As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), Dr. Duhay was instrumental in developing the TAVR program, which generates over $4.0 billion in annual revenue across 80+ countries. His experience includes leading 88 clinical studies and working with key regulatory bodies like FDA and CMS.

This appointment strengthens Pulnovo's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands internationally.

Edwards Lifesciences (NYSE: EW), a global structural heart innovation leader, has announced a $500 million accelerated share repurchase (ASR) agreement. The company will receive an initial delivery of approximately 5 million shares, with the final number to be determined based on the volume-weighted average share price during the agreement term.

This transaction brings Edwards' total share repurchases in 2025 to over $800 million. The company will fund the ASR using existing cash reserves. Following this repurchase, Edwards retains approximately $600 million in its Board-authorized share repurchase program.

Edwards Lifesciences (NYSE: EW) faces opposition from the U.S. Federal Trade Commission (FTC) regarding its proposed acquisition of JenaValve Technology. The FTC has moved to block the transaction, which Edwards believes would enhance treatment options for patients with aortic regurgitation (AR).

Despite the regulatory challenge, Edwards plans to pursue approval, expecting a final determination by Q1 2026. The company has revised its 2025 guidance, maintaining revenue projections while increasing adjusted EPS guidance to $2.45-$2.55 from $2.40-$2.50. Q3 adjusted EPS guidance remains largely unchanged.

Edwards Lifesciences (NYSE: EW) reported strong Q2 2025 financial results with sales growing 11.9% to $1.53 billion. The company's TAVR sales increased 8.9% to $1.1 billion, while TMTT sales reached $134.5 million, growing 61.9% year-over-year. Surgical sales grew 7.7% to $267 million.

The company increased its 2025 guidance, now projecting total sales growth of 9-10% to $5.9-6.1 billion, with TAVR sales guidance raised to 6-7%. Adjusted EPS guidance was raised to the high end of $2.40-$2.50. Q2 EPS was $0.57, with adjusted EPS at $0.67.

Notable achievements include SAPIEN platform's approval for asymptomatic patients in U.S. and Europe, CE Mark approval for SAPIEN M3, and strong performance across all product groups. The company maintains a stable competitive position and pricing globally.

[ "Total sales grew 11.9% to $1.53 billion, exceeding expectations", "TMTT sales surged 61.9% year-over-year to $134.5 million", "Increased 2025 sales growth guidance to 9-10% from 8-10%", "SAPIEN platform received approval for asymptomatic patients in US and Europe", "Strong cash position with approximately $3 billion in cash and cash equivalents", "Gross profit margin of 77.5% maintained in line with expectations" ]

Edwards Lifesciences (NYSE: EW), the global leader in structural heart innovation, has scheduled its Q2 2025 earnings conference call for July 24, 2025, at 5:00 p.m. ET. The company will release its operating results for the quarter ended June 30, 2025, after market close on the same day.

Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will be available live and archived on the company's investor relations website at ir.edwards.com.

Edwards Lifesciences (NYSE: EW) presented compelling evidence at EuroPCR 2025 demonstrating the benefits of early intervention in severe aortic stenosis (AS) patients. A real-world study of over 24,000 patients showed that treating AS before symptom development led to $36,000 lower healthcare costs per patient at 1 year, 2.2 fewer days of hospital stay, and 80% reduction in heart failure hospitalizations. Notably, delaying treatment until disease progression resulted in a seven times higher mortality rate within one year after aortic valve replacement. The study reinforces the importance of early referral to Heart Valve Teams and challenges the "watchful waiting" approach for severe AS management.

Edwards Lifesciences (NYSE: EW), the global leader in structural heart innovation, has announced its participation in the BofA Securities 2025 Health Care Conference on May 13, 2025. CEO Bernard Zovighian and CFO Scott Ullem will engage in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible via live webcast on Edwards' investor relations website, with a recorded version available later that day.

Edwards Lifesciences (NYSE: EW) has received FDA approval for its SAPIEN 3 TAVR (transcatheter aortic valve replacement) platform to treat asymptomatic severe aortic stenosis (AS) patients, marking the first such approval for asymptomatic cases. The approval is based on the EARLY TAVR trial results, which showed superior outcomes for TAVR compared to watchful waiting.

Key trial results with 3.8 years median follow-up showed that 26.8% of TAVR patients experienced death, stroke, or unplanned cardiovascular hospitalization, compared to 45.3% in the clinical surveillance group. The study included 455 patients in the TAVR arm and 446 in the surveillance arm. Without treatment, 1 in 10 symptomatic severe AS patients may die within five weeks.

The SAPIEN platform has treated over 1 million patients worldwide and is the most studied valve platform, with nine publications in The New England Journal of Medicine.

Edwards Lifesciences (NYSE: EW) reported strong Q1 2025 financial results with total sales growing 6.2% to $1.41 billion. The company's TAVR sales reached $1.05 billion, growing 3.8% (5.4% constant currency), while TMTT sales showed impressive growth of 58% to $115 million.

Key financial metrics include Q1 EPS of $0.62 (adjusted EPS $0.64) and a gross profit margin of 78.7%. The company received SAPIEN M3 CE Mark approval and achieved multiple TAVR study milestones.

Looking ahead, Edwards raised its TMTT sales guidance to $530-550 million and increased total company sales guidance to $5.7-6.1 billion for 2025. The company reaffirmed its adjusted EPS guidance of $2.40-2.50, accounting for JenaValve dilution and tariff impacts.